Protocol Library
Each card lists peptide research notes — vial size, example research dose range, reconstitution example, frequency example, cycle length example, and risk level. All entries are educational. Not medical advice.
5-Amino-1MQ
low riskResearched as an NNMT inhibitor in metabolic studies.
- Vial
- 50 mg
- Dose
- 50–150 mg daily (research literature, oral)
- Freq
- Once daily (research example)
- Cycle
- 4–8 weeks (research example)
Adipotide
high riskCommonly researched for adipose-tissue biology, body-composition models and obesity research in laboratory settings.
- Vial
- 10 mg
- Dose
- Published preclinical research has used very low body-weight-scaled amounts; specific human protocols are not established and are not provided here.
- Freq
- Short research courses described in preclinical literature.
- Cycle
- Short cycles in preclinical models only.
AOD-9604
low riskResearched in fat metabolism contexts.
- Vial
- 5 mg
- Dose
- 250–500 mcg daily (research literature)
- Freq
- Once daily (research example)
- Cycle
- 8–12 weeks (research example)
Bioglutide (NA-931)
moderate riskStudied in research contexts for incretin pathway activity and metabolic markers.
- Vial
- 5 mg lyophilized vial
- Dose
- Educational research dose example only.
- Freq
- Weekly in research designs.
- Cycle
- Multi-week educational examples.
Cagrilintide
moderate riskResearched for amylin receptor activity, gastric emptying and satiety endpoints.
- Vial
- 5 mg lyophilized vial
- Dose
- Commonly discussed research range: 0.3–2.4 mg weekly.
- Freq
- Weekly.
- Cycle
- 12–20 week educational example.
HGH Fragment 176-191
low riskResearched in lipolysis and adipose tissue contexts.
- Vial
- 5 mg
- Dose
- 250–500 mcg daily (research literature)
- Freq
- 1–2x daily (research example)
- Cycle
- 8–12 weeks (research example)
Lipo-C
low riskStudied for hepatic lipid metabolism research contexts.
- Vial
- Multi-dose vial (varies)
- Dose
- Educational research range varies by formulation.
- Freq
- Weekly research administration example.
- Cycle
- 4–12 week educational example.
Mazdutide
moderate riskInvestigated for combined GLP-1 and glucagon receptor activity on metabolic endpoints.
- Vial
- 5 mg lyophilized vial
- Dose
- Commonly discussed research range: 1.5–9 mg weekly.
- Freq
- Weekly.
- Cycle
- 12–24 week educational example.
Retatrutide
moderate riskResearched as a triple receptor agonist for metabolic and bodyweight studies.
- Vial
- 10 mg
- Dose
- 1 mg – 12 mg weekly (research literature)
- Freq
- Once weekly (research example)
- Cycle
- 12+ weeks (research example)
Semaglutide
moderate riskCommonly researched in studies of appetite regulation, satiety, and glucose metabolism.
- Vial
- 5 mg
- Dose
- 0.25 mg – 2.4 mg weekly (research literature)
- Freq
- Once weekly (research example)
- Cycle
- 12+ weeks (research example)
Survodutide
moderate riskInvestigated for combined incretin and glucagon receptor activity.
- Vial
- 5 mg lyophilized vial
- Dose
- Commonly discussed research range: 0.3–4.8 mg weekly.
- Freq
- Weekly.
- Cycle
- 12–24 week educational example.
Tesamorelin
moderate riskResearched in studies of visceral adipose tissue.
- Vial
- 5 mg
- Dose
- 1–2 mg daily (research literature)
- Freq
- Once daily (research example)
- Cycle
- 12+ weeks (research example)
Tirzepatide
moderate riskStudied for dual GIP/GLP-1 receptor activity in metabolic research contexts.
- Vial
- 10 mg
- Dose
- 2.5 mg – 15 mg weekly (research literature)
- Freq
- Once weekly (research example)
- Cycle
- 12+ weeks (research example)
Looking for a research supplier?
Enhanced Performance is a separate research supply platform. Visiting or purchasing is optional and not required to use PepToolbox.
Disclosure: Enhanced Performance is a separate platform connected to the owner of this website. Purchasing is optional and not required to use this tool.